Latest On Albireo Pharma, Inc (ALBO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-02 15:03 EST | News | Buyout From Ipsen: Do Not Underestimate The Value Of Albireo's Contingent Value Right | N/A |  |
| 2023-01-11 19:46 EST | News | Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition | N/A | |
| 2023-01-10 19:33 EST | News | Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade) | N/A | |
| 2023-01-09 13:07 EST | News | Albireo stock jumps 85% as Ipsen set to acquire it for ~$952M | N/A | |
| 2023-01-02 09:17 EST | News | Albireo: Slowly Capturing Some Of The Liver Disease Market | N/A | |
| 2022-12-19 14:24 EST | News | Albireo Pharma seeks to expand indication of Bylvay drug to treat excess bile buildup | N/A | |
| 2022-11-09 01:56 EST | News | Albireo Pharma GAAP EPS of -$1.92 misses by $0.04, revenue of $9.83M beats by $0.29M | N/A | |
| 2022-11-09 01:55 EST | News | Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 07:39 EST | News | Albireo Pharma Q3 2022 Earnings Preview | N/A | |
| 2022-10-13 07:18 EST | News | Albireo: Strong Phase 3 Data Foretells More Upside | N/A | |
| 2022-10-11 12:05 EST | News | Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome | N/A | |
| 2022-10-03 22:19 EST | News | Albireo Pharma: Assessing The Sagard Deal | N/A | |
| 2022-09-22 13:22 EST | News | Albireo gains on royalty agreement for pruritus therapy | N/A | |
| 2022-09-06 21:53 EST | News | Albireo gets reimbursed access to liver disease drug Bylvay in Italy | N/A | |
| 2022-08-16 20:52 EST | News | Albireo Pharma stock slips ~26% after co cuts FY sales guidance for lead drug Bylvay | N/A | |
| 2022-08-16 04:03 EST | News | Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M | N/A | |
| 2022-08-16 04:02 EST | News | Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-13 07:36 EST | News | Albireo Pharma Q2 2022 Earnings Preview | N/A | |
| 2022-07-23 04:16 EST | News | Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation | N/A | |
| 2022-05-18 02:34 EST | News | Albireo stock plunges on disappointing Q1 result | N/A | |
| 2022-05-17 03:02 EST | News | Albireo Pharma GAAP EPS of -$2.19 misses by $0.39, revenue of $6.83M misses by $0.42M | N/A | |
| 2022-05-17 03:02 EST | News | Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-14 10:34 EST | News | Albireo Pharma Q1 2022 Earnings Preview | N/A | |
| 2022-05-04 03:01 EST | News | Albireo: A Speculative Play With Upside | N/A | |
| 2022-03-01 20:40 EST | News | Albireo Pharma GAAP EPS of -$0.57, revenue of $32.52M | N/A | |
| 2022-03-01 20:40 EST | News | Albireo Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-01 20:40 EST | News | Albireo Pharma's (ALBO) CEO Ron Cooper on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-01 02:36 EST | News | Albireo Pharma Q4 2021 Earnings Preview | N/A | |
| 2022-02-02 14:38 EST | News | Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects | N/A | |
| 2022-02-01 22:21 EST | News | Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects. | N/A | |
| 2022-02-01 04:51 EST | News | Albireo: Successful And Accelerating Global Launch Drives Sales Revenue | N/A | |
| 2022-01-05 16:51 EST | News | Albireo increases 2021 Bylvay sales guidance | N/A | |
| 2021-11-25 14:50 EST | News | Albireo: Reasons For A Successful Transformation Into A Commercial Company | N/A | |
| 2021-11-05 00:43 EST | News | Albireo Pharma EPS beats by $2.41, misses on revenue | N/A | |
| 2021-11-05 00:41 EST | News | Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 03:28 EST | News | Albireo Pharma Q3 2021 Earnings Preview | N/A | |
| 2021-10-12 19:54 EST | News | Albireo inks exclusive licensing agreement with Jadeite Medicines for Bylvay in Japan | N/A | |
| 2021-09-17 12:49 EST | News | Albireo's bylvay treatment now available in Germany | N/A | |
| 2021-09-08 23:42 EST | News | UK MHRA approves Albireo's progressive familial intrahepatic cholestasis treatment Bylvay | N/A | |
| 2021-09-08 03:54 EST | News | Albireo to sell priority review voucher for $105M | N/A | |
| 2021-08-09 22:40 EST | News | Albireo Pharma: A Post Approval Assessment | N/A | |
| 2021-08-08 07:53 EST | News | Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-05 21:31 EST | News | Albireo Pharma EPS beats by $0.07, beats on revenue | N/A | |
| 2021-08-05 21:30 EST | News | Albireo Pharma, Inc. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-20 18:41 EST | News | Albireo receives positive CHMP opinion for Bylvay for rare liver disease | N/A | |
| 2021-07-20 18:32 EST | News | Albireo posts data from late-stage Bylvay liver disease study | N/A | |
| 2021-07-20 18:24 EST | News | Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress | N/A | |
| 2021-07-20 18:06 EST | News | Albireo's Bylvay OK'd in Europe for rare liver disease in children | N/A | |
| 2021-07-20 18:05 EST | News | Albireo Pharma wins FDA approval for liver disease therapy (updated) | N/A | |
| 2021-04-27 11:43 EST | News | Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat | N/A | |
About Albireo Pharma, Inc (ALBO):
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
General
- Name Albireo Pharma, Inc
- Symbol ALBO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 90
- Last Split Factor1:30
- Last Split Date2016-11-04
- Fiscal Year EndDecember
- IPO Date2007-05-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.albireopharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 70.82
- Price/Book (Most Recent Quarter) 3.88
- Enterprise Value Revenue 55.6
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$7.13
- Next Year EPS Estimate -$4.54
- Next Quarter EPS Estimate -$1.96
- Operating Margin -1159%
- Return on Assets -27%
- Return on Equity -78%
- Revenue 8.31 million
- Earnings Per Share -$5.23
- Revenue Per Share $0.52
- Gross Profit 8.31 million
- Quarterly Earnings Growth -57.8%
View More
Highlights
- Market Capitalization 662.1 million
- EBITDA -57455000
- Analyst Target Price $72.57
- Book Value Per Share $9.49
View More
Share Statistics
- Shares Outstanding 19.11 million
- Shares Float 16.64 million
- % Held by Insiders 490%
- % Held by Institutions 92.2%
- Shares Short 1.57 million
- Shares Short Prior Month 1.45 million
- Short Ratio 8.49
- Short % of Float 9%
- Short % of Shares Outstanding 8%
View More
Technicals
- Beta 1.61
- 52 Week High $43.44
- 52 Week Low $14.37
- 50 Day Moving Average 37.77
- 200 Day Moving Average 36.52
View More
Dividends
- Dividend Date 2016-11-04
- ExDividend Date N/A
- Dividend Yield 0%
View More
Albireo Pharma, Inc (ALBO) Dividend Calendar:
ALBO's last dividend payment was made to shareholders on November 4, 2016.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Albireo Pharma, Inc (ALBO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $2.72 million | -$1.30 | -$1.89 | 31.35% |
| 2020-09-30 | 2020-11-05 | $2.13 million | -$1.96 | -$1.51 | -29.8% |
| 2020-06-30 | 2020-08-06 | $N/A | -$1.38 | -$1.66 | 16.99% |
| 2020-03-31 | 2020-05-07 | $N/A | -$2.23 | -$1.39 | -60.43% |
| 2019-12-31 | 2020-03-02 | $6.43 million | -$0.57 | -$1.59 | 64.07% |
| 2019-09-30 | 2019-11-06 | $1.39 million | -$1.73 | -$1.56 | -11.16% |
| 2019-06-30 | 2019-08-08 | $1.25 million | -$1.35 | -$1.43 | 5.69% |
| 2019-03-31 | 2019-05-09 | $570000 | -$1.39 | -$1.37 | -1.56% |
| 2018-12-31 | 2019-03-06 | $571000 | -$1.34 | -$1.18 | -13.8% |
| 2018-09-30 | 2018-11-08 | $237000 | -$1.17 | -$0.98 | -19.91% |
| 2018-06-30 | 2018-08-07 | $730000 | -$1.22 | -$0.95 | -27.84% |
| 2018-03-31 | 2018-05-10 | $11.2 million | -$0.15 | -$0.20 | 26.22% |
| 2017-12-31 | 2018-03-15 | $-1000 | -$0.50 | -$0.80 | 37.37% |
| 2017-09-30 | 2017-11-14 | $-1000 | -$0.73 | -$0.85 | 14.52% |
| 2017-06-30 | 2017-08-21 | $1000 | -$0.86 | -$0.85 | -1.42% |
| 2017-03-31 | 2017-05-10 | $1000 | -$1.06 | -$0.95 | -11.58% |
| 2016-09-30 | 2016-12-22 | $28000 | -$0.74 | -$0.95 | 22.37% |
| 2016-06-30 | 2016-08-11 | $7.97 million | -$1.45 | ||
| 2016-03-31 | 2016-05-09 | $124000 | -$2.70 | -$1.20 | -125% |
| 2015-12-31 | 2016-02-16 | $5.1 million | -$1.50 | -$2.25 | 33.33% |
| 2015-09-30 | 2015-12-17 | $-7242000 | -$1.56 | -$3.22 | 51.55% |
| 2015-06-30 | 2015-08-13 | $9.66 million | -$3.60 | -$3.30 | -9.09% |
| 2015-03-31 | 2015-05-06 | $-4828000 | -$5.40 | -$6.82 | 20.82% |
| 2014-12-31 | 2015-02-12 | $2.41 million | -$6.00 | -$5.10 | -17.65% |
| 2014-09-30 | 2014-12-17 | $N/A | -$3.00 | -$7.57 | 60.37% |
| 2014-06-30 | 2014-08-11 | $N/A | -$4.50 | -$7.80 | 42.31% |
| 2014-03-31 | 2014-05-13 | $N/A | -$8.70 | -$7.20 | -20.83% |
| 2013-12-31 | 2014-02-06 | $N/A | -$3.60 | -$5.90 | 38.98% |
| 2013-09-30 | 2013-12-18 | $N/A | -$1.50 | -$9.45 | 84.13% |
| 2013-06-30 | 2013-08-12 | $N/A | -$19.80 | -$11.21 | -76.63% |
| 2013-03-31 | 2013-05-08 | $N/A | -$11.10 | -$12.75 | 12.94% |
| 2012-12-31 | 2013-02-12 | $N/A | -$7.80 | -$13.80 | 43.48% |
| 2012-09-30 | 2012-12-18 | $N/A | -$12.60 | -$13.65 | 7.69% |
| 2012-06-30 | 2012-08-08 | $N/A | -$15.60 | -$16.87 | 7.53% |
| 2012-03-31 | 2012-05-10 | $N/A | -$13.20 | -$19.50 | 32.31% |
| 2011-12-31 | 2012-02-08 | $N/A | -$14.40 | -$16.80 | 14.29% |
| 2011-09-30 | 2011-12-06 | $12.00 | -$20.91 | 157.39% | |
| 2011-06-30 | 2011-08-04 | $N/A | -$14.40 | -$25.20 | 42.86% |
| 2011-03-31 | 2011-05-05 | -$25.20 | -$31.60 | 20.25% | |
| 2010-12-31 | 2011-02-03 | -$24.00 | -$33.60 | 28.57% | |
| 2010-09-30 | 2010-12-09 | -$38.40 | -$44.64 | 13.98% | |
| 2010-06-30 | 2010-08-05 | -$43.20 | -$48.00 | 10% | |
| 2010-03-31 | 2010-05-06 | -$52.80 | -$50.20 | -5.18% | |
| 2009-12-31 | 2010-02-04 | -$56.40 | -$51.12 | -10.33% | |
| 2009-09-30 | 2009-12-10 | -$52.80 | -$60.40 | 12.58% | |
| 2009-06-30 | 2009-08-07 | -$56.40 | -$60.60 | 6.93% | |
| 2009-03-31 | 2009-05-07 | -$58.80 | -$52.46 | -12.09% | |
| 2008-12-31 | 2009-02-05 | -$50.40 | -$51.36 | 1.87% | |
| 2008-09-30 | 2008-12-10 | -$63.60 | -$54.15 | -17.45% | |
| 2008-06-30 | 2008-08-06 | -$51.60 | -$54.00 | 4.44% | |
| 2008-03-31 | 2008-05-09 | -$51.60 | -$58.20 | 11.34% | |
| 2007-12-31 | 2008-02-14 | -$66.00 | -$57.60 | -14.58% | |
| 2007-09-30 | 2007-12-12 | -$59.52 | |||
| 2007-06-30 | 2007-07-30 | -$25.20 | -$42.00 | 40% | |
| 2007-03-31 | 2007-06-16 | -$215.08 |
Albireo Pharma, Inc (ALBO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Albireo Pharma, Inc (ALBO) Chart:
Albireo Pharma, Inc (ALBO) News:
Below you will find a list of latest news for Albireo Pharma, Inc (ALBO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Albireo Pharma, Inc (ALBO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest ALBO Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 92 | $18.97 |
| Jun 13, 2022 7:59 PM EST | 2 | $18.97 |
| Jun 13, 2022 7:59 PM EST | 11 | $18.97 |
| Jun 13, 2022 7:59 PM EST | 327 | $18.96 |
| Jun 13, 2022 7:59 PM EST | 100 | $18.97 |
Albireo Pharma, Inc (ALBO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120039107/0001209191-20-039107-index.htm |
| 2020-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1322505/000000000020004303/0000000000-20-004303-index.htm |
| 2020-08-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1322505/000000000020007429/0000000000-20-007429-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000083423720008036/0000834237-20-008036-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000083423720009060/0000834237-20-009060-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000089924320002651/0000899243-20-002651-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000089924320025069/0000899243-20-025069-index.htm |
| 2019-10-30 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1322505/000090342319000329/0000903423-19-000329-index.htm |
| 2019-03-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1322505/000104746919000954/0001047469-19-000954-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1322505/000104746919002577/0001047469-19-002577-index.htm |
| 2019-05-01 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746919002796/0001047469-19-002796-index.htm |
| 2020-01-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746920000579/0001047469-20-000579-index.htm |
| 2020-01-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746920000613/0001047469-20-000613-index.htm |
| 2020-04-17 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1322505/000104746920002399/0001047469-20-002399-index.htm |
| 2020-05-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1322505/000104746920002886/0001047469-20-002886-index.htm |
| 2020-05-27 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746920003222/0001047469-20-003222-index.htm |
| 2020-09-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746920004788/0001047469-20-004788-index.htm |
| 2020-09-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1322505/000104746920004823/0001047469-20-004823-index.htm |
| 2018-10-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465918061268/0001104659-18-061268-index.htm |
| 2018-11-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1322505/000110465918067016/0001104659-18-067016-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465918067700/0001104659-18-067700-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919013162/0001104659-19-013162-index.htm |
| 2019-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919013264/0001104659-19-013264-index.htm |
| 2019-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919019486/0001104659-19-019486-index.htm |
| 2019-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1322505/000110465919023682/0001104659-19-023682-index.htm |
| 2019-04-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1322505/000110465919024067/0001104659-19-024067-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919028015/0001104659-19-028015-index.htm |
| 2019-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919036148/0001104659-19-036148-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919044722/0001104659-19-044722-index.htm |
| 2019-08-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1322505/000110465919044748/0001104659-19-044748-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465919060268/0001104659-19-060268-index.htm |
| 2020-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920008026/0001104659-20-008026-index.htm |
| 2020-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920008111/0001104659-20-008111-index.htm |
| 2020-01-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920008668/0001104659-20-008668-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920009851/0001104659-20-009851-index.htm |
| 2020-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920027610/0001104659-20-027610-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920038894/0001104659-20-038894-index.htm |
| 2020-04-17 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1322505/000110465920048176/0001104659-20-048176-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920057751/0001104659-20-057751-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920058090/0001104659-20-058090-index.htm |
| 2020-05-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1322505/000110465920061576/0001104659-20-061576-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920071096/0001104659-20-071096-index.htm |
| 2020-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920073401/0001104659-20-073401-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920091133/0001104659-20-091133-index.htm |
| 2020-08-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1322505/000110465920091487/0001104659-20-091487-index.htm |
| 2020-08-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1322505/000110465920095298/0001104659-20-095298-index.htm |
| 2020-08-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920096568/0001104659-20-096568-index.htm |
| 2020-09-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920102795/0001104659-20-102795-index.htm |
| 2020-09-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920103103/0001104659-20-103103-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920103463/0001104659-20-103463-index.htm |
| 2020-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920103960/0001104659-20-103960-index.htm |
| 2020-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920115310/0001104659-20-115310-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000110465920121584/0001104659-20-121584-index.htm |
| 2019-03-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1322505/000114036119004842/0001140361-19-004842-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000117266119000553/0001172661-19-000553-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000117266120000872/0001172661-20-000872-index.htm |
| 2018-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1322505/000119312518128767/0001193125-18-128767-index.htm |
| 2018-04-24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1322505/000119312518128786/0001193125-18-128786-index.htm |
| 2018-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000119312518189410/0001193125-18-189410-index.htm |
| 2018-07-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000119312518225299/0001193125-18-225299-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1322505/000119312518240392/0001193125-18-240392-index.htm |
| 2018-08-09 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1322505/000119312518244302/0001193125-18-244302-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000119312519037298/0001193125-19-037298-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000119312519040986/0001193125-19-040986-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000119312520032546/0001193125-20-032546-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000119312520038096/0001193125-20-038096-index.htm |
| 2020-10-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1322505/000119312520275578/0001193125-20-275578-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036906/0001209191-18-036906-index.htm |
| 2018-06-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036910/0001209191-18-036910-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036914/0001209191-18-036914-index.htm |
| 2018-06-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036918/0001209191-18-036918-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036924/0001209191-18-036924-index.htm |
| 2018-06-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036933/0001209191-18-036933-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036937/0001209191-18-036937-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036940/0001209191-18-036940-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036946/0001209191-18-036946-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036949/0001209191-18-036949-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036951/0001209191-18-036951-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036959/0001209191-18-036959-index.htm |
| 2018-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036980/0001209191-18-036980-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118037907/0001209191-18-037907-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038354/0001209191-18-038354-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038359/0001209191-18-038359-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038363/0001209191-18-038363-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038378/0001209191-18-038378-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038380/0001209191-18-038380-index.htm |
| 2018-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118038383/0001209191-18-038383-index.htm |
| 2018-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118041870/0001209191-18-041870-index.htm |
| 2018-08-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118045815/0001209191-18-045815-index.htm |
| 2018-08-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118045819/0001209191-18-045819-index.htm |
| 2018-08-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118047055/0001209191-18-047055-index.htm |
| 2018-10-12 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118054888/0001209191-18-054888-index.htm |
| 2018-10-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118054892/0001209191-18-054892-index.htm |
| 2018-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919118058716/0001209191-18-058716-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005216/0001209191-19-005216-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005220/0001209191-19-005220-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005222/0001209191-19-005222-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005224/0001209191-19-005224-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005239/0001209191-19-005239-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005241/0001209191-19-005241-index.htm |
| 2019-03-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119021454/0001209191-19-021454-index.htm |
| 2019-03-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119021457/0001209191-19-021457-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038945/0001209191-19-038945-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038952/0001209191-19-038952-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038969/0001209191-19-038969-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038971/0001209191-19-038971-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038974/0001209191-19-038974-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119038982/0001209191-19-038982-index.htm |
| 2019-11-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119054928/0001209191-19-054928-index.htm |
| 2019-11-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919119054937/0001209191-19-054937-index.htm |
| 2020-01-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120003299/0001209191-20-003299-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004740/0001209191-20-004740-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004742/0001209191-20-004742-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004748/0001209191-20-004748-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004753/0001209191-20-004753-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004755/0001209191-20-004755-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004757/0001209191-20-004757-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004759/0001209191-20-004759-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004761/0001209191-20-004761-index.htm |
| 2020-03-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120021121/0001209191-20-021121-index.htm |
| 2020-04-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120024284/0001209191-20-024284-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120025642/0001209191-20-025642-index.htm |
| 2020-04-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120025646/0001209191-20-025646-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038033/0001209191-20-038033-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038037/0001209191-20-038037-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038048/0001209191-20-038048-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038052/0001209191-20-038052-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038064/0001209191-20-038064-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120038069/0001209191-20-038069-index.htm |
| 2020-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120039107/0001209191-20-039107-index.htm |
| 2020-07-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120042210/0001209191-20-042210-index.htm |
| 2020-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120043473/0001209191-20-043473-index.htm |
| 2020-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120043475/0001209191-20-043475-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050079/0001209191-20-050079-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/0001209191-20-050081-index.htm |
| 2020-09-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050463/0001209191-20-050463-index.htm |
| 2020-09-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120052109/0001209191-20-052109-index.htm |
| 2020-10-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120054623/0001209191-20-054623-index.htm |
| 2020-10-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120055674/0001209191-20-055674-index.htm |
| 2020-10-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1322505/000120919120055676/0001209191-20-055676-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837018009015/0001558370-18-009015-index.htm |
| 2019-03-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1322505/000155837019001601/0001558370-19-001601-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837019004584/0001558370-19-004584-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837019007596/0001558370-19-007596-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837019010084/0001558370-19-010084-index.htm |
| 2020-03-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1322505/000155837020001905/0001558370-20-001905-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837020005554/0001558370-20-005554-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837020009519/0001558370-20-009519-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000155837020012727/0001558370-20-012727-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000156459018012934/0001564590-18-012934-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1322505/000156459018020960/0001564590-18-020960-index.htm |
| 2019-06-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000162363219000768/0001623632-19-000768-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1322505/000162363220000256/0001623632-20-000256-index.htm |
| 2019-04-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1322505/999999999519000929/9999999995-19-000929-index.htm |
| 2020-05-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1322505/999999999520001190/9999999995-20-001190-index.htm |
| 2020-08-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1322505/999999999520002190/9999999995-20-002190-index.htm |
| 2018-04-05 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1322505/999999999718004215/9999999997-18-004215-index.htm |
Albireo Pharma, Inc (ALBO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Albireo Pharma, Inc (ALBO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 490%Institutional Ownership: 9220%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-08 | Martha J. Carter | Chief Regulatory Officer | Sell | 10,000.00 | 45.55 | 455,500.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-09 | Martha J. Carter | Chief Regulatory Officer | Sell | 2,500.00 | 39.82 | 99,550.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-10 | Martha J. Carter | Chief Regulatory Officer | Sell | 10,000.00 | 42.41 | 424,100.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-11 | Martha J. Carter | Chief Regulatory Officer | Sell | 10,000.00 | 40.03 | 400,300.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050463/0001209191-20-050463-index.htm |
| 2020-09-08 | Martha J. Carter | Chief Regulatory Officer | Buy | 10,000.00 | 19.19 | 191,900.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-09 | Martha J. Carter | Chief Regulatory Officer | Buy | 2,500.00 | 24.04 | 60,100.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-10 | Martha J. Carter | Chief Regulatory Officer | Buy | 688.00 | 24.48 | 16,842.24 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2020-09-11 | Martha J. Carter | Chief Regulatory Officer | Buy | 938.00 | 29.76 | 27,914.88 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050463/0001209191-20-050463-index.htm |
| 2018-06-07 | JULIA R BROWN | Director | Buy | 1,500.00 | 18.54 | 27,810.00 | 1,500.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036906/0001209191-18-036906-index.htm |
| 2020-02-03 | PERCEPTIVE ADVISORS LLC | 10% Share Holder | Buy | 255,809.00 | 21.00 | 5,371,989.00 | 1,960,139.00 | https://www.sec.gov/Archives/edgar/data/1322505/000089924320002651/0000899243-20-002651-index.htm |
| 2020-09-25 | Pamela Stephenson | Chief Commercial Officer | Sell | 451.00 | 33.20 | 14,973.20 | 22,367.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120052109/0001209191-20-052109-index.htm |
| 2020-06-25 | Pamela Stephenson | Chief Commercial Officer | Sell | 397.00 | 30.79 | 12,223.63 | 22,818.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120039107/0001209191-20-039107-index.htm |
| 2020-03-25 | Pamela Stephenson | Chief Commercial Officer | Sell | 1,785.00 | 17.60 | 31,416.00 | 23,215.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120021121/0001209191-20-021121-index.htm |
| 2020-09-14 | PERCEPTIVE ADVISORS LLC | 10% Share Holder | Buy | 400,000.00 | 40.00 | 16,000,000.00 | 2,360,139.00 | https://www.sec.gov/Archives/edgar/data/1322505/000089924320025069/0000899243-20-025069-index.htm |
| 2020-09-08 | Jan Mattsson | Chief Scientific Officer | Sell | 10,000.00 | 45.55 | 455,500.00 | 24,214.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050079/0001209191-20-050079-index.htm |
| 2020-09-09 | Martha J. Carter | Chief Regulatory Officer | Sell | 7,500.00 | 38.68 | 290,100.00 | 2,500.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2019-03-25 | Pamela Stephenson | Chief Commercial Officer | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919119021457/0001209191-19-021457-index.htm | ||
| 2018-06-13 | Jan Mattsson | Chief Operating Officer | Sell | 6,903.00 | 32.08 | 221,448.24 | 34,214.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118037907/0001209191-18-037907-index.htm |
| 2020-10-22 | Jason Duncan | Chief Legal Officer and GC | Sell | 89.00 | 34.71 | 3,089.19 | 3,781.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120055674/0001209191-20-055674-index.htm |
| 2020-09-08 | Jason Duncan | Chief Legal Officer and GC | Sell | 4,000.00 | 45.55 | 182,200.00 | 3,870.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/0001209191-20-050081-index.htm |
| 2018-06-12 | Jan Mattsson | Chief Operating Officer | Sell | 2,421.00 | 33.23 | 80,449.83 | 41,117.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118037907/0001209191-18-037907-index.htm |
| 2020-10-22 | Patrick Taylor Horn | Chief Medical Officer | Sell | 89.00 | 34.55 | 3,074.95 | 4,285.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120055676/0001209191-20-055676-index.htm |
| 2018-06-12 | Jan Mattsson | Chief Operating Officer | Sell | 15,676.00 | 32.19 | 504,610.44 | 43,538.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118037907/0001209191-18-037907-index.htm |
| 2020-07-22 | Jason Duncan | Chief Legal Officer and GC | Sell | 91.00 | 25.80 | 2,347.80 | 4,370.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120043475/0001209191-20-043475-index.htm |
| 2020-07-22 | Patrick Taylor Horn | Chief Medical Officer | Sell | 91.00 | 25.80 | 2,347.80 | 4,374.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120043473/0001209191-20-043473-index.htm |
| 2020-04-22 | Jason Duncan | Chief Legal Officer and GC | Sell | 92.00 | 17.68 | 1,626.56 | 4,461.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120025642/0001209191-20-025642-index.htm |
| 2020-04-22 | Patrick Taylor Horn | Chief Medical Officer | Sell | 92.00 | 17.64 | 1,622.88 | 4,465.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120025646/0001209191-20-025646-index.htm |
| 2018-06-07 | JULIA R BROWN | Director | Buy | 3,000.00 | 17.05 | 51,150.00 | 4,500.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118036906/0001209191-18-036906-index.htm |
| 2020-01-22 | Jason Duncan | Chief Legal Officer and GC | Sell | 447.00 | 23.97 | 10,714.59 | 4,553.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004740/0001209191-20-004740-index.htm |
| 2020-01-22 | Patrick Taylor Horn | Chief Medical Officer | Sell | 443.00 | 24.29 | 10,760.47 | 4,557.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120004742/0001209191-20-004742-index.htm |
| 2020-10-12 | Simon N.R. Harford | CFO and Treasurer | Sell | 90.00 | 37.30 | 3,357.00 | 4,616.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120054623/0001209191-20-054623-index.htm |
| 2020-07-10 | Simon N.R. Harford | CFO and Treasurer | Sell | 92.00 | 25.56 | 2,351.52 | 4,706.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120042210/0001209191-20-042210-index.htm |
| 2020-04-13 | Simon N.R. Harford | CFO and Treasurer | Sell | 97.00 | 16.52 | 1,602.44 | 4,798.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120024284/0001209191-20-024284-index.htm |
| 2020-01-10 | Simon N.R. Harford | CFO and Treasurer | Sell | 105.00 | 27.20 | 2,856.00 | 4,895.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120003299/0001209191-20-003299-index.htm |
| 2019-01-22 | Jason Duncan | General Counsel | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005239/0001209191-19-005239-index.htm | ||
| 2019-01-22 | Patrick Taylor Horn | Chief Medical Officer | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919119005241/0001209191-19-005241-index.htm | ||
| 2018-10-10 | Simon N.R. Harford | CFO and Treasurer | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118054892/0001209191-18-054892-index.htm | ||
| 2018-08-14 | Ronald Harold Wilfred Cooper | President and CEO | Buy | 588.00 | 31.63 | 18,598.44 | 6,534.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118047055/0001209191-18-047055-index.htm |
| 2018-08-14 | Ronald Harold Wilfred Cooper | President and CEO | Buy | 200.00 | 32.50 | 6,500.00 | 6,734.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118047055/0001209191-18-047055-index.htm |
| 2020-09-09 | Martha J. Carter | Chief Regulatory Officer | Buy | 7,500.00 | 19.19 | 143,925.00 | 7,500.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |
| 2018-11-13 | Ronald Harold Wilfred Cooper | President and CEO | Buy | 1,026.00 | 25.02 | 25,668.16 | 7,760.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118058716/0001209191-18-058716-index.htm |
| 2018-06-07 | JULIA R BROWN | Director | Buy | 3,333.00 | 9.00 | 29,997.00 | 7,833.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919118041870/0001209191-18-041870-index.htm |
| 2020-09-08 | Jason Duncan | Chief Legal Officer and GC | Buy | 3,500.00 | 24.04 | 84,140.00 | 7,870.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050081/0001209191-20-050081-index.htm |
| 2020-09-11 | Martha J. Carter | Chief Regulatory Officer | Buy | 9,062.00 | 24.48 | 221,837.76 | 9,062.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050463/0001209191-20-050463-index.htm |
| 2020-09-10 | Martha J. Carter | Chief Regulatory Officer | Buy | 9,312.00 | 24.04 | 223,860.48 | 9,312.00 | https://www.sec.gov/Archives/edgar/data/1322505/000120919120050083/0001209191-20-050083-index.htm |